Ascendis Gets EU Committee Backing for Pediatric Achondroplasia Drug
The CHMP recommended authorization of TransCon CNP, with a European Commission decision expected in the fourth quarter of 2026.
Makkler Newsroom · Oct 16, 07:54 PM · 1 min read
Ascendis Pharma A/S ASND
NASDAQHealth TechnologyUnited States
$275.39+8.32 (+3.12%)
Market closed· · USD · Data may be delayed
- Day's range
- 265.66278.56
- 52-week range
- 188.08282.15
Financial health
– / 5
Analyst view · 22 firms
Buy21 buy · 1 hold · 0 sell
Avg. target $316.22 (+14.8%)
Prices may be delayed and are for informational purposes only - not investment advice.